A Prognostic Gene Expression Profile That Predicts Circulating Tumor Cell Presence in Breast Cancer Patients by Molloy, Timothy J. et al.
A Prognostic Gene Expression Profile That Predicts
Circulating Tumor Cell Presence in Breast Cancer Patients
Timothy J. Molloy
1, Paul Roepman
2, Bjørn Naume
3, Laura J. van’t Veer
1,2*
1Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands, 2Agendia BV, Amsterdam, The Netherlands, 3Department of
Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway
Abstract
The detection of circulating tumor cells (CTCs) in the peripheral blood and microarray gene expression profiling of the
primary tumor are two promising new technologies able to provide valuable prognostic data for patients with breast
cancer. Meta-analyses of several established prognostic breast cancer gene expression profiles in large patient cohorts have
demonstrated that despite sharing few genes, their delineation of patients into ‘‘good prognosis’’ or ‘‘poor prognosis’’ are
frequently very highly correlated, and combining prognostic profiles does not increase prognostic power. In the current
study, we aimed to develop a novel profile which provided independent prognostic data by building a signature predictive
of CTC status rather than outcome. Microarray gene expression data from an initial training cohort of 72 breast cancer
patients for which CTC status had been determined in a previous study using a multimarker QPCR-based assay was used to
develop a CTC-predictive profile. The generated profile was validated in two independent datasets of 49 and 123 patients
and confirmed to be both predictive of CTC status, and independently prognostic. Importantly, the ‘‘CTC profile’’ also
provided prognostic information independent of the well-established and powerful ‘70-gene’ prognostic breast cancer
signature. This profile therefore has the potential to not only add prognostic information to currently-available microarray
tests but in some circumstances even replace blood-based prognostic CTC tests at time of diagnosis for those patients
already undergoing testing by multigene assays.
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Introduction
Approximately one third of all women with primary breast
cancer will eventually develop metastatic disease, which represents
the final step in the progression of malignancy and is the primary
cause of mortality among cancer patients. Metastasis occurs as a
result of the movement of a single, clinically occult micrometa-
static cell from the primary tumor through the blood or lymphatic
system to a remote site, where it lodges and begins to proliferate.
The detection of these circulating tumor cells (CTCs) during their
migration is of prognostic significance, with the presence of CTCs
in the blood correlated with significantly poorer survival in both
early-stage and metastatic breast cancer patients [1,2,3]. In
addition to the prognostic value of CTC detection, it can also
be used as a tool to measure systemic treatment response –
Xenidis, et al. demonstrated that cytokeratin-19 (CK-19) mRNA-
positive circulating tumor cells (CTCs) detection in the peripheral
blood of women with early-stage breast cancer following
chemotherapy was a significant predictor of treatment success,
with patients in which CTCs remained after chemotherapy having
more frequent clinical relapses and a poorer overall survival [4].
The use of microarray technology to profile gene expression in
primary breast tumors has also resulted in the development of
several powerful tests capable of predicting outcome in cancer
[5,6,7,8,9,10]. The vast majority of these have used supervised
classification systems in which gene expression data paired with
survival information are used as inputs to build signatures that are
used to predict patient outcome. Interestingly, while these
numerous prognostic profiles only rarely have genes in common,
their classification of patients into risk categories in fact tend to be
very highly correlated, suggesting that although different signa-
tures may not include many of the same genes, they are almost
certainly looking at the same limited number of biological
pathways and processes [11,12]. We have observed that CTC
status and the ‘70-gene’ prognostic profile (currently commercially
available as the MammaPrint test) provide independent prognostic
information. In the current study, we therefore aimed to improve
upon the prognostic power of existing gene expression profiles for
breast cancer by building a gene signature predictive of CTC
status. We hypothesized that by developing a profile that
specifically predicts a tumors propensity to disseminate cells rather
than patient outcome in general, we could to identify important
gene networks that might otherwise not be found in current
profiles but were nonetheless prognostic. Such an approach may
increase the power of currently-available gene signatures for breast
cancer.
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The methods and data described herein adhere to the
REMARK criteria for the reporting of tumor marker prognostic
studies [13], and the MIAME criteria for the reporting of
microarray studies [14].
Ethics statement
Written informed consent was obtained from all participants
and the studies were approved by the Medical Ethical Committees
of the Netherlands Cancer Institute and/or The Norwegian
Radium Hospital.
Patients groups
Training cohort. In two previous studies [2,3], CTC status
was determined prior to therapy (median 14 days after diagnosis)
using multi-marker QPCR-based CTC assays (using tumour
markers TFF1, TFF3, KRT19 and EPCAM in [2] and TFF3,
SCGB2A2, KRT19 and EPCAM in [3]) at time of diagnosis for
192 women with stage I–IV breast cancer. These patients were
recruited from the outpatient clinic of The Netherlands Cancer
Institute/Antoni van Leeuwenhoek Hospital between May 2005
and May 2006. Fresh frozen primary tumor material from 72 of
these patients (29 CTC-positive and 43 CTC-negative) was
collected for micorarray analysis. All tumor specimens used were
confirmed to contain at least 50% tumour cells. The median
follow-up time for these patients was 37.4 months (Table 1). This
microarray data is publically available in NCBI’s GEO database
under accession number GSE31364 and the corresponding
clinical data is available in Table S3.
Validation cohort 1. Microarray gene expression data from
an independent cohort of 49 early-stage lymph-node negative
breast cancer patients generated in a previous study [15] was used
to validate the prediction accuracy and prognostic power of the
CTC-predictive profile. These patients also had their CTC status
determined using the same assay as for the training cohort [16]
(using tumour markers TFF3, SCGB2A2, KRT19 and EPCAM),
and have been previously described [17]. 15 of these patients
underwent systemic treatment, including 3 patients given adjuvant
chemotherapy, 11 given hormonal therapy, and 1 patient given
both chemotherapy and hormonal therapy. 18 patients were
CTC-negative, and 31 were CTC-positive. The median follow-up
time for these patients was 9.2 years (Table 1). This microarray
data is publically available in NCBI’s GEO database under
accession number GSE3985 and the corresponding clinical data
(including predicted CTC status) is available in Table S2.
Validation cohort 2. mRNA from primary breast tumor
material previously used to generate a publicly-available
microarray expression dataset [8] was recently rehybridized onto
newer, higher density whole-genome microarrays (as per [18],
which describes the rehybridization of this material onto mini-
arrays, which was performed at the same time). Microarray data
from 123 early-stage lymph-node negative patients from this
dataset, representing the lymph-node negative patient samples that
were available for rehybridization from the original 151-patient
cohort, was used for a second independent validation of the
prognostic power of CTC-predictive profile and for comparison to
the MammaPrint 70-gene prognostic profile for breast cancer
[8,9] (Table 1). 10 of these patients underwent systemic adjuvant
chemotherapy, and the median follow-up time for these patients
was 9.8 years. This microarray data is publically available
at http://microarray-pubs.stanford.edu/wound_NKI/explore.
html, and the samples from this dataset used are listed in Table S4.
Microarray analysis of training cohort
Whole-genome gene expression analysis of 72 primary breast
tumor samples from the training patient cohort was performed on
Agilent 44 k whole-genome microarrays. RNA isolation, amplifi-
cation, Cy-dye labelling and hybridization was performed as
described previously [19]. Breast tumor samples were hybridized
in a duplicate dye-swap manner against a breast cancer reference
pool that had been used previously to identify a prognostic breast
cancer signature [9]. Microarrays were scanned and analysed
using the Agilent Feature Extraction software (Agilent Technol-
ogies Inc, Santa Clara, CA). Gene expression data was corrected
for background intensities and lowess-normalized. Duplicate dye-
swap hybridizations were combined and used for the identification
of a CTC-predictive gene expression profile.
Identification of a CTC-predictive gene profile
A supervised training procedure using the microarray expres-
sion data from the training cohort was used to identify a profile
that corresponded with CTC status. A 4-fold cross validation (CV)
procedure within a leave-one-out (LOO) cross validation loop was
used to determine the optimal set of profile genes and the unbiased
profile performance on the training cohort. Within this CV
procedure, genes were scored for their association with the CTC
status (Student’s T-statistic). A set of 34 genes that were used in all
CV iterations was used for designing a ‘nearest-mean’ CTC-profile
in a similar fashion to that previously described [9,20]. The
classification threshold was chosen for high overall accuracy and
optimal positive predictive value to accurately identify tumors
derived from CTC-positive patients.
The CTC-profile was subsequently validated on an indepen-
dent microarray gene expression dataset from 49 early-stage
lymph-node negative breast cancer tumors. These had been
previously assayed using a custom cDNA microarray platform
(consisting of 42,000 features representing 24271 unique cluster
Ids; UniGene BuildNumber 173) produced at the Stanford
Functional Genomics Facility (http://www.microarray.org/sfgf/
jsp/home.jsp), and hybridised at an independent laboratory
(Radium Hospital, Oslo) [15]. This data is publically available
in the NCBI’s GEO database as GEO dataset GSE3985.
Validation was performed using 22 of the 34 CTC-profile genes
that could be mapped to the cDNA microarrays. The prognostic
value of this approximated CTC-profile was also determined
using this cohort.
A second independent validation of the prognostic value of the
CTC-predictive array-based profile was also performed using
micorarray data from 123 early-stage lymph-node negative breast
cancer patients from a second publicly-available microarray
dataset [8] [18].
Finally, the partial 22-gene CTC profile used in the first
validation cohort was also tested for predictive and prognostic
significance in the both training and second validation dataset.
Functional annotation and network analysis of CTC-
profile genes
Functional annotation of the CTC-profile genes was performed
using Ingenuity Pathway Analysis (IPA) software (Ingenuity
Systems Inc, Redwood City, CA). Statistical significance for
enrichment of functional groups within the set of 34 CTC-genes
was based on Fisher exact test and corrected for multiple testing.
Network analysis was performed using IPA and included 32 of the
34 CTC-genes (two genes could not be mapped by the IPA
software).
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Gene expression data analysis and statistical analysis was
performed in R software with additional Bioconductor packages
(www.r-project.org and www.bioconductor.org). Survival analysis
was based on Cox proportional hazard models and censored for
events not related to breast cancer progression. Classifier
performance was determined by measuring the area under the
Receiving Operating Characteristics (ROC) curve (AUC). The
optimal classifier threshold was determined on the 72 training
samples and subsequently applied to both independent validation
cohorts. All measurements were associated with 95% confidence
intervals (95% CI) and statistical tests were considered significant if
p,0.05.
Results
CTC-predictive profile
A multi-marker QPCR-based assay was previously used to
determine circulating tumor cell (CTC) status from the peripheral
blood samples of 192 breast cancer patients [2,3]. To develop a
gene expression profile that could predict CTC status, we analyzed
the primary tumors of 72 of these patients using full-genome
Agilent 44 K microarrays. A 4-fold cross validation (CV)
procedure was used to determine the optimal set of genes
expressed in the primary tumor that were associated with CTC
status. We identified a set of 34 genes which formed the CTC-
predictive profile (Table S1). The CTC-profile showed a
significant leave-one-out CV performance of 82% for the
prediction of CTC status (Figure 1) with an area under the
Receiver Operating Characteristics (ROC) curve (AUC) of 0.88
and an optimal sensitivity of 74% (95%CI: 62%–82%) and
specificity of 88% (95%CI: 79%–94%).
Independent validation and prognostic significance of
the CTC-predictive profile
Validation of the CTC-predictive profile was performed using
micorarray gene expression data from an independent cohort of
49 lymph node-negative breast cancer patients for which CTC
status had been previously determined using the same CTC
detection assay as in the training cohort [16]. This independent
validation dataset was generated using custom cDNA microarrays,
on which 22 of the 34 CTC-profile genes were present. Despite
one-third of the profile genes being missing on the platform, an
approximated CTC-profile index was calculated for each sample
(based on the threshold that was determined optimal on the
training cohort). The missing genes resulted in the lower
classification accuracy of 67.3%, with a sensitivity of 62.5% and
a specificity of 68.3%. The distribution of profile index scores was
significantly different for CTC-negative and CTC-positive patients
(p=0.004, Student’s T-test), with a median index of 20.005 and
0.175, respectively (Figure 2A), and an AUC value of 0.74
(Figure 2B). For comparison, this partial 22-gene CTC profile was
also used for classification in the training dataset. The correlation
in classification between the full 34-gene and partial 22-gene CTC
Table 1. Patient characteristics of the three cohorts used in CTC profile discovery and validation.
Characteristic Group Training Cohort Validation Cohort 1 Validation Cohort 2
Total number 72 49 123
Age ,40 5 (6.9%) 6 (12.2%) 32 (26.0%)
40–50 22 (30.6%) 5 (10.2%) 71 (57.7%)
50–60 28 (38.9%) 11 (22.4%) 20 (16.3%)
60+ 17 (23.6%) 27 (55.1%) 0 (0%)
Tumor Size pT1 (#20 mm) 47 (65.3%) 25 (51%) 48 (39.0%)
pT2 (20–50 mm) 17 (23.1%) 22 (44.9%) 73 (59.4%)
pT3 (.50 mm) 8 (11.1%) 0 (0%) 2 (1.6%)
Unknown 0 (0%) 2 (4.1%) 0 (0%)
Histological grade I 15 (20.8%) 8 (16.3%) 30 (24.4%)
II 37 (51.4%) 28 (57.1%) 37 (30.1%)
III 18 (25.0%) 13 (26.5%) 56 (45.5%)
Unknown 2 (2.8%) 0 (0%) 0 (0%)
HR status Negative 12 (16.7%) 17 (34.7%) 40 (32.5%)
Positive 58 (80.6%) 31 (63.3%) 83 (67.5%)
Unknown 2 (2.8%) 1 (2.0%) 0 (0%)
HER2/NEU status Negative 54 (75%) 38 (77.6%) 93(75.6%)
Positive 16 (22.2%) 8 (16.3%) 22 (17.9%)
Unknown 2 (2.8%) 3 (6.1%) 8 (6.5%)
CTC status Positive 31 (43.1%) 8 (16.3%) Not Determined
Negative 41 (56.9%) 41 (83.7%)
CTC profile Positive 29 (40.3%) 18 (36.7%) 81 (65.9%)
Negative 43 (59.7%) 31 (63.3%) 42 (34.1%)
MammaPrint High-risk Not Determined Not Determined 62 (50.8%)
Low-risk 60 (49.2%)
doi:10.1371/journal.pone.0032426.t001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32426Figure 1. A gene expression profile derived from the primary tumor accurately predicts the presence of CTCs in the peripheral
blood in breast cancer patients. (A) The CTC-profile indexes of 72 breast tumor samples are highly correlative with CTC status. Samples are
ordered according to CTC-profile index and colored based on CTC-status. The dashed line indicates the classification threshold with optimal
sensitivity and specificity. (B) A heatmap shows the level of expression of the 34 CTC profile genes for CTC-negative and CTC-positive patients. (C) The
ROC curve of CTC-profile indexes compared to actual CTC status.
doi:10.1371/journal.pone.0032426.g001
Figure 2. Independent validation of the CTC-predictive profile on 49 early-stage lymph-node negative breast cancer patients.
(A) Distribution of CTC-profile indexes for CTC-positive and CTC-negative patients. The dashed line indicates the threshold as was determined in the
training cohort. (B) Validation ROC curve showing classification performance of the CTC-profile. (C) Kaplan-Meier survival curves of relapse-free
survival of patients classified as CTC-positive or CTC-negative using the CTC-profile.
doi:10.1371/journal.pone.0032426.g002
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2=0.989), with an
ROC AUC of 0.873 (versus 0.876 for the full profile).
Importantly, the classification of patients using the approximat-
ed CTC-profile was prognostic (hazard ratio (HR).10 (p,0.001)),
with the patients classified as CTC profile-negative having 100%
relapse-free survival over the median 9.6-year follow-up period,
versus 73% for CTC profile-positive classified patients (Figure 2C).
Furthermore, multivariate analyses demonstrated that classifica-
tion by the CTC profile was independent of other common clinical
variables, such as tumor size, tumor grade, hormone receptor
status, HER2/NEU status, and age (Table 2A) in this cohort.
Second independent validation and comparison to 70-
gene profile
Further independent validation of the prognostic power of the
CTC-profile was performed using publically-available microarray
data from the primary tumors of 123 early-stage lymph-node
negative breast cancer patients [8]. CTC-profile classification was
determined using 33 of the 34 profile genes present on the array
platform. Classification by the CTC-profile showed a HR of 3.16
(p=0.006), confirming the prognostic value of the identified gene
set. Patients with a CTC-negative profile had a 5-year disease-free
survival (DFS) of 88% and a 10-year DFS of 83% versus 65% and
53%, respectively, for patients with a CTC-positive profile
(Figure 3A). For comparison, the partial 22-gene CTC profile
was also validated in this dataset. The correlation in classification
to the 33-gene CTC profile was again high (r
2=0.968), though it
had somewhat lower prognostic value (HR=2.56, p=0.018).
We next investigated whether the CTC-profile added any
additional independent prognostic information to the well-
established, commercially available, 70-gene ‘‘MammaPrint’’
prognostic profile [9,18]. Because more than half of the ‘70-gene’
classifier genes were missing on the arrays of the first independent
validation dataset this was performed on the second validation
dataset only. As previously reported [8], prognostic classification
based on the 70-gene MammaPrint profile was highly significant
in this patient group with a HR of 6.04 (p,0.001) and a 5-year
and 10-year DFS of 95% and 84% for MammaPrint low-risk
patients, versus 52% and 44% for MammaPrint high-risk patients
(Figure 3B). When the classification results of both profiles were
combined, risk classification was improved, with the patients
classified as low-risk by both profiles having a 100% 5-year DFS
and 91% 10-year DFS, and those patients classified as high-risk by
both profiles having a 46% 5-year DFS and 35% 10-year DFS
(Figure 3C). A multivariate analysis confirmed that despite the
strong prognostic power of the MammaPrint profile, the CTC-
profile added prognostic information with respect to disease-free
survival, which was not only independent of the MammaPrint test,
but also independent of tumor size, tumor grade, hormone
receptor status, HER2/NEU status, and age (Table 2B).
Functional annotation
Functional annotation and gene network analysis demonstrated
two main networks comprising 29 of the 34 CTC-profile genes
(Figure 4). One network (16 genes) was enriched for genes
associated with cellular survival and proliferation (p=0.001), and
included NOG, KDR, and ANKRD1. The second network (14
genes) included genes important for cellular migration (p,0.001)
and angiogenesis (p,0.01). In addition, gene networks associated
with cellular migration and adhesion made up a large proportion
of the profile which was expected due to the specific aim of the
study. These gene networks included MYH6, ICAM5, KDR,
CDH4, and AKAP5, which are important for regulating cellular
elongation and filopodia extension to enable cellular mobility, as
well as NR2E1 whose gene product interacts with the fibronectin
matrix during cellular migration, in addition to WISP1 and PAX3
which have been implicated in the epithelial-to-mesenchymal
(EMT) transition important for the distant spread of micromet-
astatic tumor cells. Of the remaining four genes, two genes were
outside these networks, and two genes were not annotated.
Discussion
We and others have previously shown that the detection of
CTCs in the peripheral blood of metastatic breast cancer patients
is a significant predictor of poor overall survival [3]. Likewise, the
detection of CTCs in the peripheral blood [21], or disseminated
tumor cells (DTCs) in the bone marrow [22] or lymph nodes [23]
in early-stage breast cancer patients is also predictive of poor
outcome. Microarray studies have demonstrated that a tumors
capacity to metastasize is apparent from very early on in its
development [9], and this is consistent with the observation that
CTCs can also be detected in breast cancer patients at the earliest
stages of their disease [2]. We therefore hypothesized that
microarray analyses of primary tumor material could be used to
generate a profile specifically predictive of a tumors’ propensity to
disseminate cells. Such a profile could supplant the need for a
separate prognostic CTC assay in certain circumstances, such as at
Table 2. Multivariate Cox regression analysis including the CTC and MammaPrint profiles in addition to common clinical variables
in the two validation cohorts of early-stage breast cancer patients.
A: Validation dataset 1 (n=49) B: Validation dataset 2 (n=123)
Clinical Variable HR (95% CI) p-value HR (95% CI) p-value
CTC profile .10 ,0.001 2.8 (1.2–6.7) 0.022
MammaPrint Not determined 5.4 (2.0–14.4) 0.001
Age (,50 years) 1.6 (0.3–9.2) 0.573 1.6 (0.5–5.0) 0.421
Tumor size (.2 cm) 2.4 (0.3–19.2) 0.397 1.3 (0.6–2.6) 0.513
Grade (.2) 2.4 (0.4–13.4) 0.320 1.5 (0.8–2.7) 0.159
ER status 4.7 (0.5–42.2) 0.168 0.6 (0.2–1.8) 0.365
PR status 0.7 (0.3–2.0) 0.533
HER2 status 0.4 (0.03–4.7) 0.434 1.0 (0.8–1.2) 0.893
Both profiles provide independent clinical information with respect to disease-free survival.
doi:10.1371/journal.pone.0032426.t002
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prognostic microarray testing. (CTC detection would remain
useful in other roles however, such as monitoring adjuvant
treatment response, or measuring changes in CTC levels over
time.) We further hypothesized that such a prognostic gene
expression signature may target pathways that may not otherwise
be represented in current prognostic microarray profiles, and may
therefore provide additional prognostic information independent
of them. Finally, such a profile may prove to be a valuable source
of CTC marker genes that could be useful in other studies.
We previously developed a highly sensitive and specific CTC
detection platform combining a dual-antigen immunomagnetic
tumor cell enrichment process with a multi-marker QPCR-based
tumor cell detection assay [24], which was used to detect CTCs in
two prospectively-collected breast cancer patient series [2,3]. In
the current study, we used whole-genome microarrays to quantify
gene expression in the primary tumors of 72 of these patients,
which led to the discovery of a 34-gene profile predictive of CTC
status (Table S1). The 34-gene ‘CTC profile’ demonstrated a
classification accuracy of 82% in this training cohort, and when
approximated using only 22 profile genes in a second, independent
microarray dataset [15] achieved a classification accuracy of 67%.
While high classification accuracy is desirable, ultimately the
value of such a profile is determined by its prognostic power. We
therefore next investigated whether the CTC-profile was prog-
nostic in this and a third microarray dataset of 123 early-stage
breast cancer patients [8]. It can be observed that more samples
(66%) were predicted to be from CTC-positive patients in this
cohort than either the first validation (37%) or training cohorts
(40%), likely due to the fact that these patients tended to have
larger, higher grade tumors (Table 1). The profile proved to be
prognostic in both independent datasets, with a HR.10 for the
first validation dataset (with the patients classified as CTC-negative
having 100% 10-year DFS; Figure 1C) and a HR of 3.2 in the
second validation dataset (Figure 3A). Importantly, multivariate
analysis confirmed that the CTC profile was providing prognostic
information independent of other clinical variables in both patient
cohorts. In these patients the CTC profile in fact was a stronger
Figure 3. Kaplan-Meier survival analysis of a second independent validation patient cohort consisting of 123 early-stage breast cancer patients from
the van de Vijver [8,18] dataset classified with the CTC-profile (A), MammaPrint 70-gene profile (B), and both classifications combined (C).
doi:10.1371/journal.pone.0032426.g003
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CTC status HR=3.6, p=0.043 for the first independent
validation cohort for which both microarray and CTC data were
available), however further studies will be required to confirm this.
A study by Fan et al. [12], which used microarray expression
data from the same publically-available dataset as was used in the
second validation cohort in the current study, demonstrated that
several prognostic profiles for breast cancer, including the
Recurrence Score [6], Wound Response [5,25], Intrinsic Subtype
[7,26], Two-Gene Ratio [27], and 70-Gene Profile (commercially
available for clinical use as the MammaPrint test) [8,9,18], were in
general highly correlated in their prognostic predictions, particu-
larly the three most prognostic – the 70-gene, recurrence score,
and wound response (p,0.001 by Chi-square test). Furthermore, a
single model derived from all three profiles was found not to be
improved compared to using any of these profiles on their own. To
test whether the same was true for the CTC profile, we compared
and combined it with the 70-gene profile in a second independent
dataset. As previously reported [8], the 70-gene profile was highly
prognostic, particularly in the first five years after diagnosis, with a
43% difference in DFS between high-risk and low-risk patients 5
years after diagnosis and a 40% difference 10 years after diagnosis
(Figure 3B). Interestingly, although having less prognostic power
than MammaPrint by itself, the CTC-profile was prognostic over
longer survival intervals - from a 23% difference for 5-year DFS
between CTC-negative and CTC-positive to 30% difference for
10-years DFS (Figure 3A). This is likely because the MammaPrint
test was specifically built to identify patients at risk of early
metastasis (chemotherapy sensitive), by distinguishing patients who
experienced progression to metastatic disease within 5 years of
diagnosis versus those who did not. Conversely the CTC profile
was built under no specific follow-up time constraints. Indeed,
accurately determining CTC status at diagnosis has the potential
to provide prognostic information over an extended period after
sampling since disseminated tumor cells have the ability to remain
dormant for many years before becoming active and forming an
overt growth [28].
Multivariate analyses demonstrated that the two profiles were
providing prognostic information not only independent of each
other, but also other common clinical variables (CTC-profile
HR=2.8 (p,0.05), 70-gene profile HR=5.4 (p,0.0001);
Table 2B): when the two profiles were combined, those patients
classified as low-risk by both profiles had a 91% 10-year DFS
(versus 84% for the MammaPrint and 83% for the CTC profiles
alone), and those patients determined to be high-risk by both
profiles had a 35% 10-year DFS (versus 44% for the MammaPrint
and 53% for the CTC profiles alone). This suggests that the
development of a model capturing the prognostic power of both
profiles could therefore complement (particularly the specificity of)
an already powerful commercially-available prognostic test for
breast cancer.
When samples from this second validation cohort were divided
by hormone receptor/HER2 status and into intrinsic subtypes
using the gene expression data [7], those classified as CTC-positive
were significantly more likely to be ER/PR/HER2-negative and
therefore of the more aggressive basal intrinsic subtype. Similarly,
those classified as CTC-negative were significantly more likely to
be of the more indolent luminal A subtype (Pearson Chi-square
analyses; data not shown). This is in contrast to the recent study of
Reyal et al. [29], which found no correlation between predicted
CTC status and subtype. This may be due to the small sample
sized used by Reyal, et al. (with only 15 CTC-positive samples
included in their study). Those patients from this cohort classified
as 70-gene ‘‘high-risk’’ were equally likely to be either ER or PR
positive or negative, and only slightly more likely to be HER2-
negative. Similarly, those patients classified as both CTC-positive
and 70-gene high risk (n=48) were equally likely to be ER-positive
or ER-negative (48% versus 52%), but significantly more likely to
be HER2-negative versus HER-2 positive (63% versus 37%,
p=0.049, Pearson Chi-square), and PR-positive than PR-negative
(63% versus 37%, p,0.031).
Functional annotation showed that, as in other studies of
prognostic gene expression profiles, genes involved in cellular
growth and proliferation were particularly overrepresented. In
Figure 4. Network analysis of CTC-profile genes indicted two main functional networks: a cellular survival/proliferation associated
network (colored orange) and a cellular migration/angiogenesis related network (colored purple). CTC-profile genes are indicated by
grey symbols.
doi:10.1371/journal.pone.0032426.g004
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adhesion made up a large proportion of the profile (14 of 34
genes), which was expected due to the specific aim of the study.
This is in contrast to our previous study [15] for which a predictive
profile for tumor cell dissemination to the bone marrow was
developed, in which genes associated with transport, ATP binding
and regulation of transcription were overrepresented (there were
in fact no genes in common between the two profiles). This may be
due to the fact that dissemination to the blood versus bone marrow
may to some extent represent distinct aspects of the disease, with
the route of dissemination reflecting the underlying biology of the
tumor. For example, we have previously shown that tumor cell
dissemination to the bone marrow tends to be more clinically
significant in less aggressive Luminal A type tumors, whereas
dissemination to the peripheral blood tends happen more often in
basal-type tumors. This would result in the genes making up the
classifier being dissimilar depending on the type of dissemination
that is being predicted. Further study of these genes could lead to
new insights into the processes of tumor cell dissemination, which
is currently imperfectly understood. None of the 6 marker genes
used in the QPCR-based detection of CTCs were present in the
CTC-profile, however one of the CTC-profile genes (ANKRD)
was identified as a strong candidate CTC marker in a previous
SAGE study undertaken by us [30]. This may also suggest that
there are other novel markers for CTC detection present in the
profile, which we are currently investigating. Both the growth/
proliferation and migration/adhesion gene networks were impor-
tant for the predictive and prognostic value of the CTC profile,
and removing genes from either significantly degraded the
performance of the classifier (data not shown).
In conclusion, we have developed a microarray signature that
can accurately predict CTC status in breast cancer patients
based on gene expression in the primary tumor, which was not
only independent of other clinical variables, but also Mamma-
Print, a prognostic microarray test used in the clinic for breast
cancer patients. In the future this may lead to a model
combining both a standard prognostic microarray test and a
CTC-predictive test for breast cancer and in this way not only
realize a significant benefit to prognostic power, but in some
circumstances also even replace blood-based prognostic CTC
tests at time of diagnosis for those patients already undergoing
testing by multigene assays.
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